For more information, contact Beth LaBreche beth@labreche.com 612-578-2834 New VP will work to make the Vivally® System accessible to 46 million people in the US
Maker of the Vivally® System wearable neuromodulation system for bladder issues passes rigorous standards for safety and quality Columbus, OH March. 4, 2024 Avation Medical,
Vivally is the first FDA-cleared, noninvasive, closed-loop, wearable tibial neuromodulation system and digital companion app for urge urinary incontinence and urinary urgency caused by overactive bladder (OAB) syndrome
Vivally is the first FDA-cleared, noninvasive, closed-loop, wearable tibial neuromodulation system and digital companion app for urge urinary incontinence and urinary urgency caused by overactive bladder (OAB) syndrome
Vivally is the first FDA-cleared, noninvasive, closed-loop, wearable tibial neuromodulation system and digital companion app for urge urinary incontinence and urinary urgency caused by overactive bladder (OAB) syndrome
Vivally® System, wearable closed-loop neuromodulation system and mobile application for urge
incontinence and urinary urge, recognized by MedTech Breakthrough Awards program for 2023
Revolutionary smart, wearable bladder control therapy and mobile app provides a new option
for urge urinary incontinence and urinary urgency for patients with no surgery, implants, or drugs
Avation Medical is pioneering a wearable digital therapy that could soon change the way that chronic health conditions are monitored and treated.
Avation Medical’s Kimberly Wilkinson was recognized by The Healthcare Technology Report in its recent announcement of The Top 25 Healthcare Tech Leaders of Houston, TX
Medical Devices and Diagnostic Industries announced a keynote panel discussion at BIOMedevice Boston to occur on Thu, Sep 29, 2022. Six female medical device industry executives will team
Avation Medical is proud to share that our CEO, Jill Schiaparelli, has been named one of the Top 25 Women Leaders in Consumer Health Tech
Dr. Colin Goudelocke, investigator in the “FreeOAB Study”, will present the results of Avation Medical’s recent clinical trial evaluating the safety and efficacy of a
